why choose us

First received: January 04, 2023

Clinical Trial: A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Brief Summary: To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma.The safety and effects of this drug combination will also be studied

Read more